Payment overview · 2025
General Payments
$1,131.13
60 reported records · 18 companies
Healthcare provider profile · identity verified
Quasir Raza, MD
Allopathic & Osteopathic Physicians|Internal Medicine · ROANOKE, VA · NPI 1497846943
Verified facts
What the public records show
CMS Open Payments records show Quasir Raza, MD received $1,131.13 in general payments during 2025 across 60 reported records.
Amgen Inc. accounted for 15.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 27 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Linzess, Mounjaro, Ozempic, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Vraylar by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 131 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 111 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 464 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $174.37 | 15.4% | 16 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $155.50 | 13.8% | 5 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $149.12 | 13.2% | 8 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $99.34 | 8.8% | 5 | 2025 |
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $78.98 | 7.0% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $69.01 | 6.1% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $53.02 | 4.7% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $51.34 | 4.5% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $49.18 | 4.3% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $39.27 | 3.5% | 2 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $37.56 | 3.3% | 2 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $34.89 | 3.1% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $29.36 | 2.6% | 2 | 2025 |
| Tonix Medicines, Inc. | Unresolved — no canonical attribution shown | $24.15 | 2.1% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $22.60 | 2.0% | 1 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $22.52 | 2.0% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$22.10 | 1.9% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $18.82 | 1.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,131.13 | 60 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $174.37 | 16 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $155.50 | 14 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $149.12 | 8 | 2025 |
Source payment records
|
|||||
| Rystiggo Normalized: rystiggo |
Drug | UCB, Inc. | $94.91 | 3 | 2025 |
Source payment records
|
|||||
| VYVGART HYTRULO Normalized: vyvgart hytrulo |
Drug | ARGENX US, INC. | $78.98 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $69.01 | 3 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $60.95 | 3 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $60.95 | 3 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $60.95 | 3 | 2025 |
Source payment records
|
|||||
| Zilbrysq Normalized: zilbrysq |
Drug | UCB, Inc. | $60.59 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $53.02 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $51.34 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $46.64 | 2 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $37.56 | 2 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $34.89 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $34.69 | 2 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $34.69 | 2 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $29.36 | 2 | 2025 |
Source payment records
|
|||||
| TONMYA Normalized: tonmya |
Drug | Tonix Medicines, Inc. | $24.15 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $22.60 | 1 | 2025 |
Source payment records
|
|||||
| SYNCHROMEDII Normalized: synchromedii |
Device | Medtronic, Inc. | $22.10 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $21.16 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $21.16 | 1 | 2025 |
Source payment records
|
|||||
| VYNDAMAX Normalized: vyndamax |
Drug | PFIZER INC. | $21.12 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $18.82 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $18.11 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $14.49 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 33 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 47 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 60 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 111 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 33 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 78 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
47 | 14 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
84 | 23 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
78 | 21 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
131 | 27 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
60 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
77 | 15 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
111 | 25 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
464 | 106 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
14 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1409 | 407 |
| Amlodipine Besylate | Amlodipine Besylate | 1399 | 389 |
| Levothyroxine Sodium | Levothyroxine Sodium | 782 | 200 |
| Pantoprazole Sodium | Pantoprazole Sodium | 754 | 234 |
| Losartan Potassium | Losartan Potassium | 662 | 180 |
| Metformin Hcl | Metformin Hcl | 608 | 172 |
| Lisinopril | Lisinopril | 467 | 133 |
| Eliquis | Apixaban | 464 | 106 |
| Duloxetine Hcl | Duloxetine Hcl | 437 | 114 |
| Gabapentin | Gabapentin | 430 | 135 |
| Metoprolol Tartrate | Metoprolol Tartrate | 419 | 118 |
| Omeprazole | Omeprazole | 415 | 114 |
| Metoprolol Succinate | Metoprolol Succinate | 410 | 111 |
| Simvastatin | Simvastatin | 374 | 96 |
| Tamsulosin Hcl | Tamsulosin Hcl | 372 | 113 |
| Meloxicam | Meloxicam | 353 | 127 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 351 | 105 |
| Trazodone Hcl | Trazodone Hcl | 331 | 90 |
| Furosemide | Furosemide | 322 | 100 |
| Hydrochlorothiazide | Hydrochlorothiazide | 303 | 95 |
| Potassium Chloride | Potassium Chloride | 289 | 86 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 285 | 86 |
| Sertraline Hcl | Sertraline Hcl | 271 | 76 |
| Carvedilol | Carvedilol | 259 | 80 |
| Montelukast Sodium | Montelukast Sodium | 244 | 64 |
| Fluoxetine Hcl | Fluoxetine Hcl | 237 | 61 |
| Valsartan | Valsartan | 229 | 64 |
| Clopidogrel | Clopidogrel Bisulfate | 226 | 66 |
| Ezetimibe | Ezetimibe | 213 | 60 |
| Azithromycin | Azithromycin | 202 | 127 |
| Allopurinol | Allopurinol | 200 | 54 |
| Mirtazapine | Mirtazapine | 187 | 55 |
| Pravastatin Sodium | Pravastatin Sodium | 183 | 49 |
| Fluticasone Propionate | Fluticasone Propionate | 181 | 71 |
| Prednisone | Prednisone | 181 | 105 |
| Famotidine | Famotidine | 173 | 61 |
| Farxiga | Dapagliflozin Propanediol | 166 | 47 |
| Glimepiride | Glimepiride | 161 | 45 |
| Escitalopram Oxalate | Escitalopram Oxalate | 158 | 50 |
| Bupropion Xl | Bupropion Hcl | 157 | 40 |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 154 | 41 |
| Doxazosin Mesylate | Doxazosin Mesylate | 151 | 45 |
| Pregabalin | Pregabalin | 149 | 52 |
| Finasteride | Finasteride | 147 | 41 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 146 | 40 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 145 | 56 |
| Spironolactone | Spironolactone | 144 | 40 |
| Donepezil Hcl | Donepezil Hcl | 143 | 37 |
| Torsemide | Torsemide | 140 | 31 |
| Hydralazine Hcl | Hydralazine Hcl | 137 | 46 |
| Jardiance | Empagliflozin | 131 | 27 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 131 | 37 |
| Oxybutynin Chloride | Oxybutynin Chloride | 124 | 35 |
| Xarelto | Rivaroxaban | 124 | 21 |
| Methylprednisolone | Methylprednisolone | 121 | 101 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 119 | 26 |
| Amitriptyline Hcl | Amitriptyline Hcl | 118 | 25 |
| Ozempic | Semaglutide | 111 | 25 |
| Ropinirole Hcl | Ropinirole Hcl | 110 | 30 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 110 | 61 |
| Alprazolam | Alprazolam | 109 | 25 |
| Nebivolol Hcl | Nebivolol Hcl | 109 | 36 |
| Buspirone Hcl | Buspirone Hcl | 107 | 40 |
| Celecoxib | Celecoxib | 106 | 33 |
| Doxycycline Hyclate | Doxycycline Hyclate | 104 | 77 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 103 | 30 |
| Clonidine Hcl | Clonidine Hcl | 102 | 29 |
| Tramadol Hcl | Tramadol Hcl | 95 | 33 |
| Clonazepam | Clonazepam | 92 | 27 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 92 | 26 |
| Citalopram Hbr | Citalopram Hydrobromide | 91 | 26 |
| Entresto | Sacubitril/Valsartan | 90 | 18 |
| Warfarin Sodium | Warfarin Sodium | 90 | 21 |
| Labetalol Hcl | Labetalol Hcl | 89 | 26 |
| Metformin Hcl Er | Metformin Hcl | 89 | 28 |
| Irbesartan | Irbesartan | 86 | 21 |
| Aripiprazole | Aripiprazole | 84 | 27 |
| Cephalexin | Cephalexin | 84 | 73 |
| Synthroid | Levothyroxine Sodium | 84 | 23 |
| Alendronate Sodium | Alendronate Sodium | 83 | 25 |
| Cefdinir | Cefdinir | 79 | 71 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 78 | 21 |
| Trulicity | Dulaglutide | 77 | 15 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 75 | 24 |
| Repaglinide | Repaglinide | 75 | 22 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 74 | 21 |
| Atenolol | Atenolol | 73 | 19 |
| Quetiapine Fumarate | Quetiapine Fumarate | 73 | 17 |
| Topiramate | Topiramate | 72 | 19 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 70 | 22 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 68 | 17 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 68 | 53 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 68 | 18 |
| Lovastatin | Lovastatin | 67 | 21 |
| Zolpidem Tartrate | Zolpidem Tartrate | 67 | 13 |
| Chlorthalidone | Chlorthalidone | 66 | 20 |
| Ondansetron Hcl | Ondansetron Hcl | 66 | 38 |
| Diclofenac Sodium | Diclofenac Sodium | 64 | 33 |
| Sucralfate | Sucralfate | 64 | 31 |
| Nystatin | Nystatin | 62 | 38 |
| Colchicine | Colchicine | 61 | 22 |
| Januvia | Sitagliptin Phosphate | 61 | 13 |
| Lorazepam | Lorazepam | 61 | 15 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 60 | 20 |
| Mounjaro | Tirzepatide | 60 | 16 |
| Klor-Con M20 | Potassium Chloride | 59 | 21 |
| Myrbetriq | Mirabegron | 59 | 24 |
| Tradjenta | Linagliptin | 58 | 19 |
| Azelastine Hcl | Azelastine Hcl | 57 | 37 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 57 | 19 |
| Pioglitazone Hcl | Pioglitazone Hcl | 56 | 21 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 55 | 14 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 55 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 54 | 15 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 53 | 47 |
| Propranolol Hcl | Propranolol Hcl | 53 | 15 |
| Fenofibrate | Fenofibrate | 52 | 14 |
| Paroxetine Hcl | Paroxetine Hcl | 52 | 12 |
| Fenofibrate | Fenofibrate Nanocrystallized | 51 | 15 |
| Temazepam | Temazepam | 51 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 51 | 20 |
| Cefuroxime | Cefuroxime Axetil | 50 | 49 |
| Enalapril Maleate | Enalapril Maleate | 50 | 15 |
| Indapamide | Indapamide | 50 | 14 |
| Memantine Hcl | Memantine Hcl | 50 | 17 |
| Tresiba Flextouch U-200 | Insulin Degludec | 50 | 14 |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 49 | 14 |
| Risperidone | Risperidone | 48 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 47 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 47 | 13 |
| Linzess | Linaclotide | 47 | 14 |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 46 | 12 |
| Ramipril | Ramipril | 45 | 11 |
| Amoxicillin | Amoxicillin | 42 | 29 |
| Levetiracetam | Levetiracetam | 41 | 16 |
| Baclofen | Baclofen | 40 | 18 |
| Fluconazole | Fluconazole | 39 | 22 |
| Dicyclomine Hcl | Dicyclomine Hcl | 38 | 12 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 38 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 37 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 37 | 11 |
| Hydrocortisone | Hydrocortisone | 36 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 35 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 35 | 24 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 35 | suppressed |
| Glipizide Er | Glipizide | 34 | suppressed |
| Lamotrigine | Lamotrigine | 34 | 11 |
| Levofloxacin | Levofloxacin | 34 | 29 |
| Breo Ellipta | Fluticasone/Vilanterol | 33 | suppressed |
| Creon | Lipase/Protease/Amylase | 33 | suppressed |
| Rybelsus | Semaglutide | 33 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 32 | 17 |
| Nitroglycerin | Nitroglycerin | 32 | 13 |
| Tresiba Flextouch U-100 | Insulin Degludec | 32 | suppressed |
| Diazepam | Diazepam | 31 | 14 |
| Glipizide | Glipizide | 31 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 31 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 31 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 30 | 12 |
| Doxepin Hcl | Doxepin Hcl | 30 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 29 | 21 |
| Droplet Pen Needle | Pen Needle, Diabetic | 28 | suppressed |
| Sotalol | Sotalol Hcl | 28 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 27 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 27 | suppressed |
| Novolog Flexpen | Insulin Aspart | 27 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 26 | 13 |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 26 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 26 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 25 | 22 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 25 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 25 | 11 |
| Cholestyramine Light | Cholestyramine | 24 | suppressed |
| Methocarbamol | Methocarbamol | 24 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 23 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 23 | suppressed |
| Lagevrio (Eua) | Molnupiravir | 23 | 23 |
| Lidocaine | Lidocaine | 23 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 23 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 23 | suppressed |
| Estradiol | Estradiol | 22 | suppressed |
| Eszopiclone | Eszopiclone | 22 | suppressed |
| Klor-Con M10 | Potassium Chloride | 22 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 22 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 22 | 21 |
| Folic Acid | Folic Acid | 21 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 21 | 11 |
| Methimazole | Methimazole | 21 | suppressed |
| Nabumetone | Nabumetone | 21 | suppressed |
| Ramelteon | Ramelteon | 21 | suppressed |
| Acyclovir | Acyclovir | 20 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 20 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 20 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 20 | suppressed |
| Nifedipine Er | Nifedipine | 20 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Cilostazol | Cilostazol | 19 | suppressed |
| Clindamycin Phosphate | Clindamycin Phosphate | 19 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 19 | 13 |
| Clonidine | Clonidine | 19 | suppressed |
| Gemfibrozil | Gemfibrozil | 19 | suppressed |
| Olanzapine | Olanzapine | 19 | suppressed |
| Ondansetron Odt | Ondansetron | 19 | 14 |
| Verapamil Er | Verapamil Hcl | 19 | suppressed |
| Bumetanide | Bumetanide | 18 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 18 | suppressed |
| Metronidazole | Metronidazole | 18 | 17 |
| Bupropion Hcl Sr | Bupropion Hcl | 17 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 17 | suppressed |
| Levemir Flexpen | Insulin Detemir | 17 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 17 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 17 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Crestor | Rosuvastatin Calcium | 16 | suppressed |
| Diclofenac Sodium Er | Diclofenac Sodium | 16 | suppressed |
| Fluocinonide | Fluocinonide | 16 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 15 | suppressed |
| Ketoconazole | Ketoconazole | 15 | suppressed |
| Methotrexate | Methotrexate Sodium | 15 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 15 | 13 |
| Roflumilast | Roflumilast | 15 | suppressed |
| Telmisartan | Telmisartan | 15 | suppressed |
| Vascepa | Icosapent Ethyl | 15 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 14 | 14 |
| Primidone | Primidone | 14 | suppressed |
| Tadalafil | Tadalafil | 14 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 14 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 13 | suppressed |
| Brilinta | Ticagrelor | 13 | suppressed |
| Buprenorphine | Buprenorphine | 13 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 13 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 13 | suppressed |
| Felodipine Er | Felodipine | 13 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Lansoprazole | Lansoprazole | 13 | suppressed |
| Ranolazine Er | Ranolazine | 13 | suppressed |
| Zafirlukast | Zafirlukast | 13 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 12 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 12 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 12 | suppressed |
| Silodosin | Silodosin | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Armour Thyroid | Thyroid,pork | 11 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 11 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 11 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Livalo | Pitavastatin Calcium | 11 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 11 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 11 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 11 | suppressed |
| Semglee (Yfgn) Pen | Insulin Glargine-Yfgn | 11 | suppressed |
| Sotalol Af | Sotalol Hcl | 11 | suppressed |
| Vraylar | Cariprazine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,131.13 · 60 records | Amgen Inc. | ABRYSVO, CAPLYTA, COMIRNATY, CREON, FREESTYLE LIBRE 3, INSPIRE, KISUNLA, LINZESS, MOUNJARO, OTEZLA, Ohtuvayre, Ozempic, PREVNAR 20, QULIPTA, REPATHA, REXULTI, Rybelsus, Rystiggo, SYNCHROMEDII, TONMYA, TRELEGY ELLIPTA, VERQUVO, VOQUEZNA, VYNDAMAX, VYVGART HYTRULO, ZEPBOUND, Zilbrysq | 13 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error